Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,025 public trials 2,027 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

NCT03543813

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +29 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • California Cancer Associates for Research and Excellence Encinitas, California, United States
  • University of Southern California Los Angeles, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
View all 25 locations
View Trial Details
Completed

Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

NCT03976102

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • The Oncology Institute of Hope and Innovation Whittier, California, United States
  • American Oncology Partners of Maryland Bethesda, Maryland, United States
  • University of Tennessee Medical Center - Cancer Institute Knoxville, Tennessee, United States
  • Gulf coast Oncology Associates, PA Houston, Texas, United States
View Trial Details
Completed

Selinexor, Cyclophosphamide and Prednisone in Myeloma

NCT06212596

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Birmingham Heartlands Hospital Birmingham, United Kingdom
  • Royal Bournemouth Hospital Bournemouth, United Kingdom
  • Leicester Royal Infirmary Leicester, United Kingdom
  • Royal Liverpool University Hospital Liverpool, United Kingdom
View all 13 locations
View Trial Details
Completed

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04657302

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations
  • Beijing Cancer Hospital Beijing, China
  • Peking University Third Hospital Beijing, China
  • Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology Guangzhou, China
  • Harbin Medical University Cancer Hospital Harbin, China
View Trial Details
Completed

My Choices: Efficacy and Implementation Study

NCT05358613

Conditions
Alcohol Drinking, Alcohol Use Disorder, Mild, Alcohol Use, Unspecified, +17 more
Locations
  • Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay-Lac-Saint-Jean Jonquière, Quebec, Canada
  • Centre Intégré de Santé Services Sociaux de Laval Laval, Quebec, Canada
  • Centre intégré de Santé et de Services Sociaux de Chaudière-Appalaches Lévis, Quebec, Canada
  • Centre Intégré Universitaire de Santé et de Services Sociaux de la Capitale-Nationale Québec, Canada
View Trial Details
Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

NCT03833180

Conditions
Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +49 more
Locations
  • City of Hope ( Site 0010) Duarte, California, United States
  • University of California - San Diego ( Site 0003) La Jolla, California, United States
  • UCLA Hematology & Oncology ( Site 0007) Los Angeles, California, United States
  • University of Nebraska Medical Center ( Site 0006) Omaha, Nebraska, United States
View all 14 locations
View Trial Details

Related conditions